- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Zydena ( Udenafil )
Zydena (udenafil) is a phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult men. It works by selectively inhibiting the PDE5 enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum of the penis. During sexual stimulation, nitric oxide is released from cavernosal nerve terminals and endothelial cells, activating the enzyme guanylate cyclase and increasing intracellular cGMP concentrations. Elevated cGMP levels induce smooth muscle relaxation in the corpus cavernosum, promoting increased arterial blood flow and venous compression, which together produce and sustain an erection. By inhibiting PDE5-mediated breakdown of cGMP, udenafil enhances and prolongs the erectile response to sexual arousal. Udenafil is distinguished from other PDE5 inhibitors by its relatively long half-life, which provides an extended therapeutic window compared to sildenafil. It is important to note that Zydena is not approved by Health Canada, and its sale in Canada is not authorized. Patients should be aware that unapproved products obtained from unregulated sources may pose significant health risks, including unknown ingredients, inconsistent dosing, and lack of manufacturing quality control.
Usual adult dose: The recommended dose of udenafil is 100 mg taken as needed approximately 30 to 60 minutes before anticipated sexual activity. Based on individual efficacy and tolerability, the dose may be adjusted to 200 mg in patients who do not achieve a satisfactory response with the 100 mg dose. The maximum recommended dose is 200 mg per single use, and the maximum dosing frequency is once daily. Udenafil may be taken with or without food; unlike sildenafil, the absorption of udenafil is not significantly affected by a high-fat meal. For patients with mild to moderate hepatic impairment or mild to moderate renal impairment, no routine dose adjustment is required; however, caution is advised, and a lower starting dose of 50 mg may be considered in patients with severe renal or hepatic disease. Udenafil is absolutely contraindicated in patients taking any form of organic nitrate or nitric oxide donors, including nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and amyl nitrite, due to the risk of severe, potentially fatal hypotension. Concurrent use with alpha-blockers requires caution due to the additive blood-pressure-lowering effects.
Dosage form: Tablets: 100 mg. Zydena is typically encountered as pale yellow, oval-shaped, film-coated tablets for oral administration. Due to the unregulated nature of this product in Canada, the appearance, excipients, and actual udenafil content may vary widely between sources and cannot be verified for purity, potency, or safety.
Onset of action: Following oral administration, udenafil is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations achieved at approximately 0.5 to 1.5 hours after dosing, with a median time to peak of approximately 60 minutes. The onset of the pro-erectile effect may be apparent as early as 30 minutes after ingestion in some men, and the therapeutic window allows for a more flexible approach to the timing of sexual activity compared with shorter-acting PDE5 inhibitors. Sexual stimulation is required for udenafil to facilitate an erection; the medication does not induce erections in the absence of arousal.
Duration of action: The elimination half-life of udenafil is approximately 11 to 13 hours, which is significantly longer than that of sildenafil (3 to 4 hours) and tadalafil (17.5 hours). The extended half-life provides a therapeutic duration of up to 24 hours in some patients, permitting a wider window of opportunity for sexual activity. This prolonged duration of action has led to udenafil being characterized as a long-acting PDE5 inhibitor suitable for once-daily or on-demand use depending on the clinical context. Priapism, defined as a painful erection lasting more than 4 hours, is a rare but medical emergency requiring immediate intervention to prevent permanent erectile dysfunction.
Alcohol recommendation: Alcohol consumption should be minimized or avoided when using udenafil. Both alcohol and PDE5 inhibitors possess vasodilatory properties; when combined, they may produce additive reductions in systemic blood pressure, leading to dizziness, lightheadedness, headache, facial flushing, or tachycardia. Excessive alcohol intake is independently associated with erectile dysfunction and may impair the ability to achieve or maintain an erection sufficient for satisfactory sexual intercourse, thereby counteracting the therapeutic benefit of the medication. Patients who choose to drink alcohol while using udenafil should limit intake to small amounts and understand how the combination affects them before engaging in activities requiring alertness or physical exertion.
Most common side effects: Facial flushing, headache, dyspepsia (indigestion), nasal congestion, and dizziness. Facial flushing and headache are the most frequently reported adverse effects, occurring in approximately 10% to 15% of users and typically correlating with the vasodilatory effects of PDE5 inhibition. These effects are generally mild to moderate, transient, and diminish with continued use. Ocular side effects, including blurred vision and altered color perception, occur less frequently with udenafil than with sildenafil, reflecting its higher selectivity for PDE5 over PDE6. Myalgia and back pain, which are relatively common with tadalafil, are less frequently reported with udenafil. As with all PDE5 inhibitors, priapism is a rare but serious adverse event requiring emergency medical evaluation. Additional concerns with unregulated products like Zydena include exposure to unknown contaminants, inaccurate labeling of active ingredient content, substitution with other PDE5 inhibitors, and the absence of patient safety information and medical oversight. Patients with pre-existing cardiovascular disease, including recent myocardial infarction, unstable angina, severe heart failure, or uncontrolled arrhythmias, should undergo a thorough medical assessment before using any PDE5 inhibitor, as sexual activity itself carries an inherent degree of cardiac risk.
Would you like to learn more about safe and Health Canada-approved treatment options for erectile dysfunction?
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
+ Free standard airmail service
+ Package delivery insurance
+ Next orders 10% discount
